How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

11,625 results for

Intrauterine Device

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. Copper intrauterine device placement 6-14days after unprotected sex. Full Text available with Trip Pro

Copper intrauterine device placement 6-14days after unprotected sex. To evaluate pregnancy risk following copper (CuT380A) intrauterine device (IUD) placement 6-14 days after unprotected intercourse.We used a combined dataset from four protocols in which participants had received a CuT380A IUD regardless of recent unprotected intercourse. At entry, participants had negative point of care urine pregnancy testing and reported all acts of unprotected intercourse in the two weeks prior to IUD

2019 Contraception

42. Depot Medroxyprogesterone Acetate, Oral Contraceptive, Intrauterine Device Use, and Fracture Risk. (Abstract)

Depot Medroxyprogesterone Acetate, Oral Contraceptive, Intrauterine Device Use, and Fracture Risk. To assess fracture risk among women with depot medroxyprogesterone acetate (DMPA), oral contraceptive pill (OCP), and intrauterine device (IUD) use.A retrospective cohort study of 308,876 women age 12-45 years who initiated DMPA, combined or progestin-only OCPs, and copper and levonorgestrel IUDs from 2005 to 2015. Cumulative DMPA, OCP, and IUD use was assessed. Time since last DMPA injection

2019 Obstetrics and Gynecology

43. A 1-year comparison of TCu380Ag versus TCu380A intrauterine contraceptive devices in India. (Abstract)

A 1-year comparison of TCu380Ag versus TCu380A intrauterine contraceptive devices in India. To compare TCu380Ag and TCu380A intrauterine contraceptive devices after 1 year of use.A prospective randomized controlled trial was conducted among healthy married women aged 20-35 years who attended the family planning clinics of three tertiary centers in India between August 1, 2015, to March 31, 2018. The TCu380Ag group (n=300) received one of three sizes of this device depending on uterocervical

2019 International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics Controlled trial quality: predicted high

44. Use of Intrauterine Devices and Risk of HIV Acquisition among Insured Women in the U.S. (Abstract)

Use of Intrauterine Devices and Risk of HIV Acquisition among Insured Women in the U.S. Concerns have been raised about progestin-containing contraceptives and risk of HIV acquisition. Based on health insurance data from 622,565 women in the U.S. with intrauterine device (IUD) insertions during 2011-2018, there was no increased risk of incident HIV diagnosis among women using levonorgestrel-releasing IUDs compared with those using copper IUDs.© The Author(s) 2019. Published by Oxford University

2019 Clinical Infectious Diseases

45. Intrauterine Device Insertion Procedure Duration in Adolescent and Young Adult Women. (Abstract)

Intrauterine Device Insertion Procedure Duration in Adolescent and Young Adult Women. Intrauterine device (IUD) utilization in the United States is low among adolescent and young adult women. Longer procedure duration has been proposed as one potential barrier to IUD insertion in this population. We hypothesized that procedure duration would be longer in adolescents compared to young adult women.This study was a secondary analysis of a randomized clinical trial comparing the effectiveness

2019 Journal of pediatric and adolescent gynecology Controlled trial quality: uncertain

46. Paracervical Block for Intrauterine Device Placement Among Nulliparous Women: A Randomized Controlled Trial. (Abstract)

Paracervical Block for Intrauterine Device Placement Among Nulliparous Women: A Randomized Controlled Trial. 30575660 2018 12 21 1873-233X 133 1 2019 Jan Obstetrics and gynecology Obstet Gynecol Paracervical Block for Intrauterine Device Placement Among Nulliparous Women: A Randomized Controlled Trial. 189 10.1097/AOG.0000000000003043 Levine Elliot M EM Department of Obstetrics and Gynecology, Advocate Aurora Health Illinois Masonic Medical Center, Chicago, Illinois. Fernandez Carlos M CM eng

2019 Obstetrics and Gynecology Controlled trial quality: predicted high

47. “Repeal and replace”: increased demand for intrauterine devices following the 2016 presidential election. (Abstract)

“Repeal and replace”: increased demand for intrauterine devices following the 2016 presidential election. To evaluate public's interest in contraceptive options following heightened focus on a repeal of the Affordable Care Act (ACA) since the 2016 United States presidential election.We monitored the fraction of Google searches emerging from the United States for the three most popular reversible contraceptive methods - oral contraceptives, intrauterine devices (IUDs) and condoms - from January

2019 Contraception

48. Migration of an intrauterine device causing severe hydronephrosis progressing to renal failure: A case report. Full Text available with Trip Pro

Migration of an intrauterine device causing severe hydronephrosis progressing to renal failure: A case report. Intrauterine device (IUD) is commonly used in China. Its complications include uterine perforation, IUD ectopic migration, etc. However, a migrated IUD rarely leads to renal failure.IUD insertion in the patient was followed by unexplained pain in the left renal area, without bladder irritation or dysuresia.Hydronephrosis, renal failure, migrated IUD.The patient underwent laparoscopic

2019 Medicine

49. Reducing Pain During Intrauterine Device Insertion: A Randomized Controlled Trial in Adolescents and Young Women (Abstract)

Reducing Pain During Intrauterine Device Insertion: A Randomized Controlled Trial in Adolescents and Young Women To estimate the effect of a 1% lidocaine paracervical nerve block on pain during intrauterine device (IUD) insertion compared with a sham block in adolescents and young women.We conducted a multisite, single-blind, sham-controlled randomized trial in adolescents and young women having a 13.5-mg levonorgestrel IUD inserted. Enrollment occurred at three family planning clinics

2017 EvidenceUpdates

50. Chronic nodules of sigmoid perforation caused by incarcerated intrauterine contraception device. Full Text available with Trip Pro

Chronic nodules of sigmoid perforation caused by incarcerated intrauterine contraception device. It is extremely rare for an intrauterine contraception device (IUD) to cause uterine perforation and Sigmoid perforation for a long time without being detected.We present a case of a patient who has suffered from abdominal pain after 4 years of placement of an IUD, and found that the IUD was incarcerated by ultrasound.Laparoscopic and hysteroscopic examination revealed that the incarcerated IUD (...) caused uterine perforation and sigmoid perforation for a long time. One end of the intrauterine device completely penetrated the anterior wall muscle layer of the uterus and the full layer of the sigmoid colon, located in the intestinal lumen, and the perforated portion of the sigmoid colon formed a chronic nodule.We extended the sigmoid colon perforation and uterine perforation by laparoscopy, removed the incarcerated IUD from the uterus through the vagina, trimmed the chronic nodules of the sigmoid

2019 Medicine

51. Hysteroscopic Intrauterine Morcellation for Benign Intrauterine Pathologies: Clinical Effectiveness and Guidelines

and Guidelines Last updated: October 23, 2018 Project Number: RB1267-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of hysteroscopic intrauterine morcellation for the removal of benign intrauterine pathologies? What are the evidence-based guidelines regarding the management of an unsuspected malignancy diagnosed in patients who have previously undergone hysteroscopic intrauterine morcellation (...) Hysteroscopic Intrauterine Morcellation for Benign Intrauterine Pathologies: Clinical Effectiveness and Guidelines Hysteroscopic Intrauterine Morcellation for Benign Intrauterine Pathologies: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Hysteroscopic Intrauterine Morcellation for Benign Intrauterine Pathologies: Clinical Effectiveness and Guidelines Hysteroscopic Intrauterine Morcellation for Benign Intrauterine Pathologies: Clinical Effectiveness

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review

52. The efficacy of intrauterine devices for emergency contraception: a systematic review of 35 years of experience

The efficacy of intrauterine devices for emergency contraception: a systematic review of 35 years of experience Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

53. Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature

Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

54. Ultrasound-guided intrauterine device insertion: a step closer to painless insertion: a randomised control trial. (Abstract)

Ultrasound-guided intrauterine device insertion: a step closer to painless insertion: a randomised control trial. 29260589 2018 04 27 2018 12 02 1473-0782 23 2 2018 04 The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception Eur J Contracept Reprod Health Care Ultrasound-guided intrauterine device insertion: a step closer to painless insertion: a randomised control trial. 165 10.1080/13625187.2017.1413180 Abbas Ahmed M AM (...) a Department of Obstetrics and Gynecology, Faculty of Medicine , Assiut University , Assiut , Egypt. eng Letter Comment 2017 12 20 England Eur J Contracept Reprod Health Care 9712127 1362-5187 IM Eur J Contracept Reprod Health Care. 2017 Oct;22(5):349-353 28978240 Humans Intrauterine Device Expulsion Intrauterine Devices Intrauterine Devices, Medicated 2017 12 21 6 0 2018 4 28 6 0 2017 12 21 6 0 ppublish 29260589 10.1080/13625187.2017.1413180

2018 The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception Controlled trial quality: predicted high

55. Dual-responsive lidocaine in situ gel reduces pain of intrauterine device insertion. (Abstract)

Dual-responsive lidocaine in situ gel reduces pain of intrauterine device insertion. The most effective and safe contraceptive method, intrauterine devices (IUDs), is still underutilized due to the pain barrier during IUD insertion. Lidocaine, a well-known local anesthetic, can be used to relieve IUD insertion pain. This study aimed at formulation, in vitro, in vivo and clinical evaluation of a novel lidocaine dual-responsive in situ gel. Pluronic and Gelrite® were used as thermosenstive

2018 International journal of pharmaceutics Controlled trial quality: uncertain

56. Placement of Levonorgestrel Intrauterine Device at the Time of Cesarean Delivery and the Effect on Breastfeeding Duration. Full Text available with Trip Pro

Placement of Levonorgestrel Intrauterine Device at the Time of Cesarean Delivery and the Effect on Breastfeeding Duration. Studies have shown that immediate postpartum initiation of long-acting reversible contraception (LARC) methods leads to increased utilization of LARC and prevention of unintended pregnancies. It is unclear if immediate postpartum levonorgestrel-releasing intrauterine device (LNG-IUD) insertion has an effect on breastfeeding success.This study was a secondary analysis (...) of a randomized trial that compared intrauterine device (IUD) use at 6 months postpartum among women who underwent intracesarean IUD placement with women who planned for interval IUD placement at 6 or more weeks postpartum. This parallel, 1:1, nonblinded randomized trial was conducted between March 2012 and June 2014 at the University of North Carolina Women's Hospital. We recruited pregnant women aged 18-45 years who were undergoing a cesarean delivery and desired an IUD for contraception postpartum.We

2018 Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine Controlled trial quality: uncertain

57. The role of the Mirena Intrauterine Device(LNG-IUD) in the management of endometrial polyps - a Pilot Study. (Abstract)

The role of the Mirena Intrauterine Device(LNG-IUD) in the management of endometrial polyps - a Pilot Study. To study the hypothesis that the levonorgestrel intrauterine device (LNG-IUD) can have a role in the treatment of endometrial polyps confirmed at outpatient hysteroscopy in premenopausal women.Canadian Task Force classification level II1 (a controlled trial that is not randomised).Outpatient hysteroscopy.Premenopausal women who had a polyp diagnosed at outpatient

2018 Journal of minimally invasive gynecology Controlled trial quality: uncertain

58. Use of a novel suction cervical retractor for intrauterine device insertion: a pilot feasibility trial. (Abstract)

Use of a novel suction cervical retractor for intrauterine device insertion: a pilot feasibility trial. The Bioceptive suction cervical retractor (SCR) is a novel device that can replace the standard single-tooth tenaculum to place traction on the cervix. A feasibility trial was conducted on the device for intrauterine device (IUD) placement.Our three-stage feasibility process began with Stage 1, where the device was tested on in-vitro and ex-vivo samples. In Stage 2, 10 women received (...) their IUD using the device. In Stage 3, a feasibility trial, we randomly assigned 25 consenting women to receive their IUD using either the Bioceptive SCR or the standard single-tooth tenaculum. In Stages 2 and 3, we collected pain scores using an electronically adapted 100-point visual analogue scale (VAS) at eight timepoints during and after the insertion procedure, as well as satisfaction and acceptability measures. The primary outcome was the pain score after attaching the SCR or tenaculum (VAS 3

2018 BMJ Sexual & Reproductive Health Controlled trial quality: uncertain

59. Lidocaine for pain control during intrauterine device insertion. (Abstract)

Lidocaine for pain control during intrauterine device insertion. The aim of this study was to compare the effects of topical lidocaine spray, cream and injection on pain perception during intrauterine device (IUD) insertion.Multiparous women of reproductive age were randomized into control, lidocaine cream, spray and injection groups. A 10 cm visual analog scale was used for all patients to evaluate pain during the three steps of the IUD insertion procedure. Baseline pain assessment was made

2018 The journal of obstetrics and gynaecology research Controlled trial quality: uncertain

60. Oral Ketorolac for Pain Relief During Intrauterine Device Insertion: A Double-Blinded Randomized Controlled Trial. (Abstract)

Oral Ketorolac for Pain Relief During Intrauterine Device Insertion: A Double-Blinded Randomized Controlled Trial. To evaluate if oral ketorolac provides effective pain relief during placement of an IUD for contraception.We conducted a double-blinded randomized controlled trial in a community hospital in Columbus, Ohio. Participants that met eligibility criteria were consented and randomized to receive either oral ketorolac 20 mg or placebo 40 to 60 minutes before IUD placement. Both

2018 Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC Controlled trial quality: predicted high

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>